These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare

Canadian biotech stock BELLUS Health has been snatched from the public market. However, these two biopharma growth stocks also have the capacity to change healthcare.

| More on:
Workers use a microscope to do medical research in a modern laboratory.

Source: Getty Images

Early investors in Canadian biotech stock BELLUS Health (TSX:BLU) could be ecstatic right now after a fine 75.5% rally in BLU stock year to date. The bullish run was ensued after global pharmaceuticals giant GSK offered to acquire all BELLUS stock at US$14.75, or a 103% premium to BLU stock’s previous market price. The transaction received a 99.99% vote by BLU shareholders on June 16, 2023.

A promising clinical-stage Canadian biotech stock has been snatched from the public market. BELLUS Health is developing a potential best-in-class refractory chronic cough therapy, camlipixant, that has reached the final (phase three) testing stage. BLU stock investors could realize up to 847% in returns over a five-year holding period. BELLUS stock has finally handsomely rewarded its faithful investors, despite its struggle to recover from a 2020 drop. Buyouts similar to the BELLUS-GSK deal usually happen when a target company is developing a healthcare solution with significant potential to change lives.

That said, we still have several Canadian small-cap biotech stocks whose research teams are working tirelessly to change the face of healthcare. Two Canada-based biotech stocks come to mind. Let’s have a look.

AbCellera Biologics

AbCellera Biologics (NASDAQ:ABCL) is a biotech development company that’s using artificial intelligence (AI) to discover antibodies that may be used to treat or cure several health conditions. The Vancouver-based Canadian biotech firm has extensively partnered with emerging biotech firms and well-established pharmaceutical companies. It leverages its proprietary data science-optimized platform to help partners develop medicines faster than ever before.

Banking on a strong balance sheet, the company has committed $401 million to a $701 million co-investment partnership with the government of Canada and British Columbia to strengthen drug development capabilities and help change the face of Canadian healthcare.

ABCL stock trades down 88% off from its highs recorded at its initial public offering (IPO) in late 2020. AbCellera Biologics’s revenue generation has gone down in 2023 because the emergency-use authorization from the U.S. Food and Drug Administration (FDA) on a partnered COVID-19 treatment, bebtelovimab, expired in 2022. However, the biotech stock could be getting ripe for bottom fishing.

The company saw a 20% jump in the number of partnered program starts to 101, and it increased its discovery partners by 14% year over year to 41 during the first quarter of 2023. Its revenue opportunity set is growing.   

Insiders at AbCellera acquired 167,500 shares in ABCL stock worth more than US$1.1 million during the past three months. They seem confident of the company’s potential to grow revenue and influence how medicines are developed and commercialized in North America.

  • We just revealed five stocks as “best buys” this month … join Stock Advisor Canada to find out if Enbridge made the list!

Xenon Pharmaceuticals

Xenon Pharmaceuticals (NASDAQ:XENE) is a British Columbia, Canada-based neurology-focused biotech stock. The clinical-stage biopharmaceutical firm is developing an epilepsy drug program, the XEN1101, that has reached the final (phase three) trial stages and could be commercialized soon to change patient lives.

Although several antiseizure medications are available, the company sees a significant unmet medical need in up to 50% of American patients that have difficulty controlling seizures or have severe refractory epilepsy.

The company is well funded with nearly US$690 million in cash, cash equivalence, and marketable securities on March 31, 2023. The assets could fund the company’s activities well in 2026, including the completion of the current phase three epilepsy drug trials.

XENE stock has produced 397% in returns to investors over the past five years. The Canada-based biotech stock has quietly changed some investors’ lives already.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbCellera Biologics. The Motley Fool has a disclosure policy.

More on Tech Stocks

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

1 Bright Canadian AI Stock Ready to Surge in 2025 and Beyond

Don't run away from tech stocks, this AI stock could surge this year and beyond.

Read more »

A microchip in a circuit board powers artificial intelligence.
Tech Stocks

An AI Giant Hiding in Plain Sight: Why Wall Street Is Missing Shopify’s Tech Edge

Shopify (TSX:SHOP) stock is a top Canadian AI play that could break out to new highs in 2025.

Read more »

Abstract Human Skull representing AI
Tech Stocks

Step Aside, Nvidia: This AI Stock Is the Real Deal for Canadian Investors

Canada has several tech companies pivoting to AI, which isn't the same as pure-breed AI stocks, but that's not necessarily…

Read more »

A shopper makes purchases from an online store.
Tech Stocks

Prediction: Here’s Where Shopify Will Land at Year-End

For long-term growth investors, Shopify (TSX:SHOP) has been a winner worth owning. Will that continue moving forward?

Read more »

space ship model takes off
Tech Stocks

1 TSX Powerhouse Ready for Takeoff

Constellation Software (TSX:CSU) is a top tech play that could still surge amid looming tariffs.

Read more »

Sharing secrets
Tech Stocks

Want to Invest in Quantum Computing? 1 Stock That Is a Great Buy Right Now.

The quantum hype might not be all it seems. See why you should pay closer attention to surprisingly familiar names…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

2 Cheap-Looking Stocks to Could Win in the AI Revolution

It's about time we gave firms like Thomson Reuters (TSX:TRI) a bit more of an AI premium.

Read more »

bulb idea thinking
Tech Stocks

The Smartest Canadian Stock to Buy With $1,000 Right Now

Strong financials, booming demand for its services, and an expanding presence in AI and cloud computing hardware make Celestica the…

Read more »